{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-036597","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.054550+00:00","generated_at":"2026-05-31T10:00:07.158058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Esperion Q2 revenue jumps 186% to $73.8M; monetizes European royalties for $304.7M","bullets":["Total revenue $73.8M (+186% YoY); U.S. product revenue $28.3M (+39% YoY).","Monetized European royalties to OMERS for $304.7M; used proceeds to pay off Oberland facility and remove liens.","Net loss $61.9M ($0.33 loss per share) vs $49.9M loss in Q2 2023; cash $189.3M.","Retail prescription equivalents increased 11% in final four weeks of Q2; >21,000 prescribers.","Reiterated FY2024 operating expense guidance $225M-$245M; patent extension for bempedoic acid to Dec 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-036597","json":"https://secwatch.observer/filing/0001628280-24-036597.json","markdown":"https://secwatch.observer/filing/0001628280-24-036597.md","text":"https://secwatch.observer/filing/0001628280-24-036597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024036597/0001628280-24-036597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024036597/espr-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:00:07.158058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}